Core Insights - Spero Therapeutics, Inc. is focused on developing tebipenem HBr, an investigational oral carbapenem aimed at treating complicated urinary tract infections (cUTI), including pyelonephritis [1] Group 1: Clinical Development - The Phase 3 trial (PIVOT-PO) for tebipenem HBr has successfully met its primary endpoint and was stopped early due to positive results [1]

SEATTLE, Feb. 11, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet need, today issued a letter to Shareholders from Steven Quay, M.D., Ph.D., Atossa Therapeutics President and Chief Executive Officer, providing an update on the Company's clinical programs and recent events. The full text of the letter follows: Regulatory and Development Strategy - Clarity ...

Core Insights - Candel Therapeutics, Inc. is focused on developing multimodal biological immunotherapies for cancer treatment and will present at the 7th Annual Glioblastoma Drug Development Summit in February 2026 [1] Company Overview - Candel Therapeutics is a clinical-stage biopharmaceutical company that develops off-the-shelf multimodal biological immunotherapies aimed at eliciting systemic anti-tumor immune responses [4] - The company has established two clinical-stage platforms based on genetically modified adenovirus and herpes simplex virus (HSV) gene constructs [4] - The lead product candidate from the adenovirus platform is aglatimagene besadenovec (CAN-2409), which has completed successful phase 2a trials in non-small cell lung cancer and pancreatic ductal adenocarcinoma, and is undergoing a pivotal phase 3 trial in localized prostate cancer [4] Product Development - Linoserpaturev (CAN-3110) is the lead candidate from the HSV platform, currently in a phase 1b clinical trial for recurrent high-grade glioma [5] - In October 2023, results from a clinical trial indicated that linoserpaturev was well tolerated with no dose-limiting toxicity, showing improved median overall survival compared to historical controls after a single injection [3] - The company is supported by the Break Through Cancer foundation to evaluate repeated linoserpaturev injections in patients with recurrent glioblastoma [3] Upcoming Presentations - Dr. Francesca Barone will present insights on Candel's HSV-based platform and the linoserpaturev program at the summit, including a workshop on patient stratification and a conference presentation on integrating biomarkers and imaging [2][3]

Core Viewpoint - Catalyst Pharmaceuticals, Inc. will release its fourth quarter and full-year 2025 financial results on February 25, 2026, followed by a conference call and webcast on February 26, 2026, at 8:30 AM ET to discuss these results and provide a business update [1][2]. Group 1: Financial Results Announcement - The company will announce its financial results after the market close on February 25, 2026 [1]. - A conference call and webcast will be held on February 26, 2026, at 8:30 AM ET to discuss the financial results [2]. Group 2: Conference Call & Webcast Details - The US/Canada dial-in number for the conference call is (800) 715-9871, and the international dial-in number is (646) 307-1963 [3]. - The webcast will be accessible on the company's website, with a replay available for at least 30 days following the event [3]. Group 3: Company Overview - Catalyst Pharmaceuticals is focused on developing and commercializing novel medicines for patients with rare diseases [4]. - The company has been recognized by Forbes as one of America's Most Successful Companies in 2023, 2024, and 2025, and listed on the 2025 Deloitte Technology Fast 500™ as one of North America's Fastest-Growing Companies [4].

Core Insights - MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on precision peptide therapies for endocrine and metabolic disorders [1][3] - The company will participate in two upcoming investor conferences, providing opportunities for engagement with investors [2] Company Overview - MBX Biosciences specializes in the discovery, development, and commercialization of novel precision peptide therapies using its proprietary PEP™ platform [3] - The company is advancing a pipeline that includes canvuparatide (MBX 2109) for chronic hypoparathyroidism, which is preparing for Phase 3 development [3] - The obesity portfolio includes MBX 4291 in Phase 1 development and several discovery and pre-clinical candidates [3] - Imapextide (MBX 1416) is in Phase 2 development for post-bariatric hypoglycemia [3] - The company is based in Carmel, Indiana [3]

Full Year and Q4 2025 Financial Results February 11, 2026 Forward Looking Statements This presentation has been prepared by Royalty Pharma plc (the "Company"), is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this presentation unless stated otherwise, and ne ...

Core Viewpoint - Soleno Therapeutics, Inc. is set to report its fourth quarter and full-year 2025 financial results on February 25, 2026, along with operational highlights, followed by a conference call to discuss these results and business updates [1]. Group 1: Financial Reporting - The financial results will be announced after the close of U.S. financial markets on February 25, 2026 [1]. - A conference call and webcast will take place at 4:30 PM Eastern Time to discuss the results [1][2]. Group 2: Company Overview - Soleno Therapeutics focuses on developing and commercializing novel therapeutics for rare diseases [3]. - The company's first commercial product is VYKAT XR (diazoxide choline) extended-release tablets, which is a once-daily oral treatment for hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [3].

Core Insights - PolyPid Ltd. is advancing discussions for a commercial partnership in the U.S. for its product D-PLEX₁₀₀, following positive Phase 3 trial results and FDA engagement [3][5] - The company expects to begin the rolling NDA submission process by the end of Q1 2026, marking a significant step towards regulatory approval [3][5] - 2026 is anticipated to be a transformative year for PolyPid as it transitions from late-stage development to full commercial execution [3][14] Recent Corporate Highlights - The completion of the SHIELD II Phase 3 trial has positioned D-PLEX₁₀₀ for advanced partnership discussions in the U.S. [3][5] - Positive FDA feedback supports the planned rolling NDA submission for D-PLEX₁₀₀ aimed at preventing surgical site infections [5][14] - Brooke Story has been appointed as Chairman of the Board, bringing extensive experience in medical technology [5] - A Key Opinion Leader event highlighted the clinical and economic burden of surgical site infections and the potential of D-PLEX₁₀₀ to improve outcomes [5] Financial Results - For Q4 2025, R&D expenses decreased to $6.2 million from $7.0 million in Q4 2024, reflecting the completion of the SHIELD II trial [6] - G&A expenses increased to $1.8 million in Q4 2025 from $1.0 million in Q4 2024, while marketing expenses rose to $0.6 million from $0.2 million [6] - The net loss for Q4 2025 was $8.5 million, or $0.41 per share, compared to a net loss of $8.5 million, or $1.13 per share, in Q4 2024 [7][20] Full Year Financial Overview - For the full year 2025, R&D expenses totaled $23.8 million, up from $22.8 million in 2024, driven by trial completion and regulatory preparations [13] - G&A expenses for 2025 were $7.2 million, compared to $4.3 million in 2024, primarily due to non-cash expenses related to performance-based options [13] - The net loss for 2025 was $34.2 million, or $2.09 per share, compared to a net loss of $29.0 million, or $4.91 per share, in 2024 [13][18] Balance Sheet Highlights - As of December 31, 2025, the company had cash and cash equivalents of $6.4 million, down from $15.6 million in 2024 [15] - Total assets decreased to $22.3 million in 2025 from $25.2 million in 2024 [16] - Shareholders' equity increased to $10.973 million in 2025 from $7.684 million in 2024, reflecting additional capital raised through warrant exercises [13][17]

Core Viewpoint - Nuvectis Pharma, Inc. has made significant progress in its NXP900 development program during 2025, with multiple potential data readouts expected in 2026, while maintaining a focus on operational execution and financial responsibility [2]. Financial Results - As of December 31, 2025, the company's cash and cash equivalents increased to $31.6 million from $18.5 million in 2024, reflecting a rise of $13.1 million due to a public offering and access to an at-the-market facility, partially offset by operating expenses [3]. - The net loss for the year ended December 31, 2025, was $26.4 million, an increase of $7.4 million compared to a net loss of $19.0 million in 2024. This loss included $6.0 million in non-cash stock-based compensation and one-time license fees of $2.4 million [4]. - Research and development expenses for 2025 were $18.2 million, up from $12.9 million in 2024, marking an increase of $5.3 million. General and administrative expenses rose to $9.4 million from $6.9 million, an increase of $2.5 million [5]. - Finance income for 2025 was $1.1 million, compared to $0.8 million in 2024, reflecting an increase of $0.3 million [6]. Company Overview - Nuvectis Pharma, Inc. is focused on developing innovative precision medicines for serious unmet medical needs in oncology, with its primary asset being NXP900, an oral small molecule inhibitor targeting SRC Family Kinases [7].

Core Viewpoint - NorthStrive Biosciences Inc. has entered into a definitive exclusive license agreement with Modulant Biosciences LLC to develop and commercialize animal health products based on its EL-22 and EL-32 assets, marking a significant milestone for the company [1][6]. Group 1: License Agreement Details - The License Agreement grants Modulant an exclusive, royalty-bearing, sublicensable license to develop, manufacture, and commercialize products derived from EL-22 and EL-32 for non-human animal health applications, excluding the Republic of Korea [2]. - Modulant is responsible for all development, manufacturing, regulatory, and commercialization activities for the licensed products, with a focus on using commercially reasonable efforts [4]. - The agreement includes issued patents, pending patent applications, and associated proprietary know-how related to the EL-22 and EL-32 programs [4]. Group 2: Product and Market Implications - EL-22 and EL-32 target myostatin and activin-A pathways, which are crucial for muscle development, strength, and metabolic efficiency, and are increasingly important in animal health and nutrition applications [3]. - The collaboration aims to advance EL-22 and EL-32-derived products toward commercialization in the growing global animal health market, driven by rising demand for improved animal performance, wellness, and longevity [5]. Group 3: Company Background - NorthStrive Biosciences Inc. focuses on developing cutting-edge aesthetic medicines, with its lead asset EL-22 addressing muscle preservation during weight loss treatments [8]. - PMGC Holdings Inc., the parent company of NorthStrive, is a diversified holding company that seeks growth through strategic acquisitions and investments across various industries [9]. Group 4: Modulant Biosciences Overview - Modulant Biosciences LLC specializes in veterinary medicine innovation, focusing on developing novel drugs and biologics for various animal types, including livestock and companion animals [11].